Identification of new cytotoxic T-lymphocyte epitopes from cancer testis antigen HCA587

Biochemical and Biophysical Research Communications

Volumn 372, Issue 2, 2008, Pages 331-335

  Xing, Qiao ^a   Pang, Xue Wen ^a   Peng, Ji Run ^b   Yin, Yan Hui ^a   Li, Yan ^a   Yu, Xin ^b   Zhou, Shu Pei ^a   Zhang, Yu ^a   Chen, Wei Feng ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Cancer testis antigen; Cytotoxic T cells; Hepatocellular carcinoma; Peptides epitopes

Indexed keywords

CANCER TESTIS ANTIGEN; CANCER TESTIS ANTIGEN HCA587; EPITOPE; HLA A ANTIGEN; HLA A1 ANTIGEN; HLA A2 ANTIGEN; PEPTIDE DERIVATIVE;

ANTIGEN PURIFICATION; ARTICLE; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG MECHANISM; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VITRO STUDY; LIVER CELL CARCINOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PROTEIN TARGETING;

AMINO ACID SEQUENCE; ANTIGENS, NEOPLASM; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; EPITOPE MAPPING; EPITOPES, T-LYMPHOCYTE; HLA-A ANTIGENS; HUMANS; IMMUNOTHERAPY; LIVER NEOPLASMS; MALE; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; PEPTIDES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 44649138526     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.05.049     Document Type: Article

References (20)

1. Masaki T., Morishita A., Kurokohchi K., and Kuriyama S. Multidisciplinary treatment of patients with hepatocellular carcinoma. Expert Rev. Anticancer Ther. 6 (2006) 1377-1384
2. Hanke P., Rabe C., Serwe M., Bohm S., Pagenstecher C., Sauerbruch T., and Caselmann W.H. Cirrhotic patients with or without hepatocellular carcinoma harbour AFP-specific T-lymphocytes that can be activated in vitro by human alpha-fetoprotein. Scand. J. Gastroenterol. 37 (2002) 949-955
3. Scanlan M.J., Gure A.O., Jungbluth A.A., Old L.J., and Chen Y.T. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol. Rev. 188 (2002) 22-32
4. + responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant. Proc. Natl. Acad. Sci. USA 101 (2004) 9363-9368
5. van Baren N., Bonnet M.C., Dreno B., Khammari A., Dorval T., Piperno-Neumann S., Lienard D., Speiser D., Marchand M., Brichard V.G., Escudier B., Negrier S., Dietrich P.Y., Maraninchi D., Osanto S., Meyer R.G., Ritter G., Moingeon P., Tartaglia J., van der Bruggen P., Coulie P.G., and Boon T. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J. Clin. Oncol. 23 (2005) 9008-9021
6. Wang Y., Han K.J., Pang X.W., Vaughan H.A., Qu W., Dong X.Y., Peng J.R., Zhao H.T., Rui J.A., Leng X.S., Cebon J., Burgess A.W., and Chen W.F. Large scale identification of human hepatocellular carcinoma-associated antigens by autoantibodies. J. Immunol. 169 (2002) 1102-1109
7. Lucas S., De Plaen E., and Boon T. MAGE-B5, MAGE-B6, MAGE-C2, and MAGE-C3: four new members of the MAGE family with tumor-specific expression. Int. J. Cancer 87 (2000) 55-60
8. Gure A.O., Stockert E., Arden K.C., Boyer A.D., Viars C.S., Scanlan M.J., Old L.J., and Chen Y.T. CT10: a new cancer-testis (CT) antigen homologous to CT7 and the MAGE family, identified by representational-difference analysis. Int. J. Cancer 85 (2000) 726-732
9. Li B., Qian X.P., Pang X.W., Zou W.Z., Wang Y.P., Wu H.Y., and Chen W.F. HCA587 antigen expression in normal tissues and cancers: correlation with tumor differentiation in hepatocellular carcinoma. Lab. Invest. 83 (2003) 1185-1192
10. Li B., He X., Pang X., Zhang H., Chen J., and Chen W. Elicitation of both CD4 and CD8 T-cell-mediated specific immune responses to HCA587 protein by autologous dendritic cells. Scand. J. Immunol. 60 (2004) 506-513
11. Germeau C., Ma W., Schiavetti F., Lurquin C., Henry E., Vigneron N., Brasseur F., Lethe B., De Plaen E., Velu T., Boon T., and Coulie P.G. High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J. Exp. Med. 201 (2005) 241-248
12. + T cell epitope from hepatocellular carcinoma-associated antigen HCA587. Clin. Exp. Immunol. 140 (2005) 310-319
13. + T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients. Clin. Cancer Res. 10 (2004) 6946-6955
14. Mizukoshi E., Nakamoto Y., Marukawa Y., Arai K., Yamashita T., Tsuji H., Kuzushima K., Takiguchi M., and Kaneko S. Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma. Hepatology 43 (2006) 1284-1294
15. Lecoeur H., Fevrier M., Garcia S., Riviere Y., and Gougeon M.L. A novel flow cytometric assay for quantitation and multiparametric characterization of cell-mediated cytotoxicity. J. Immunol. Methods 253 (2001) 177-187
16. Brichard V., Van Pel A., Wolfel T., Wolfel C., De Plaen E., Lethe B., Coulie P., and Boon T. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 178 (1993) 489-495
17. Davis I.D., Chen W., Jackson H., Parente P., Shackleton M., Hopkins W., Chen Q., Dimopoulos N., Luke T., Murphy R., Scott A.M., Maraskovsky E., McArthur G., MacGregor D., Sturrock S., Tai T.Y., Green S., Cuthbertson A., Maher D., Miloradovic L., Mitchell S.V., Ritter G., Jungbluth A.A., Chen Y.T., Gnjatic S., Hoffman E.W., Old L.J., and Cebon J.S. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc. Natl. Acad. Sci. USA 101 (2004) 10697-10702
18. Ma W., Germeau C., Vigneron N., Maernoudt A.S., Morel S., Boon T., Coulie P.G., and Van den Eynde B.J. Two new tumor-specific antigenic peptides encoded by gene MAGE-C2 and presented to cytolytic T lymphocytes by HLA-A2. Int. J. Cancer 109 (2004) 698-702
19. Larsen M.V., Lundegaard C., Lamberth K., Buus S., Brunak S., Lund O., and Nielsen M. An integrative approach to CTL epitope prediction: a combined algorithm integrating MHC class I binding, TAP transport efficiency, and proteasomal cleavage predictions. Eur. J. Immunol. 35 (2005) 2295-2303
20. Nielsen M., Lundegaard C., Lund O., and Kesmir C. The role of the proteasome in generating cytotoxic T-cell epitopes: insights obtained from improved predictions of proteasomal cleavage. Immunogenetics 57 (2005) 33-41